natgillin/translations-raw huggingface dataset:
CD20-molekylet er et transmembrant phosphoprotein, der udtrykkes på B-lymfocytter fra præ-B-lymfocytstadiet til stadiet, hvor B-lymfocytterne er modne, samt på B-celletumorer.
The CD20 molecule is a transmembrane phosphoprotein expressed on B lymphocytes from the pre-B to mature B lymphocyte stage and on B cell tumours.
CD3 på overfladen af T-celler (celler i immunsystemet, der er ansvarlige for at dræbe sygdomsfremkaldende celler og kræftceller).
CD3 on the surface of T-cells (cells of the immune system responsible for killing pathogens and cancer cells).
CD3+- og CD4+-lymfocyttal stiger langsommere mod normalen, men er generelt ikke vendt tilbage til baseline ved 12-måneders postbehandling.
CD3+ and CD4+ lymphocyte counts rise more slowly towards normal, but generally do not return to baseline by
CD34+-celler/kg: x 106
CD34+ cells/kg: x 106
CD4 Gennemsnitsændring fra baseline, celler/mm3
CD4 Mean Change from Baseline, cells/mm3
CD4 Middelændring fra Baseline, celler/mm3
CD4 Mean Change from Baseline, cells/mm3
CD4 Middelændring fra Baseline, celler/mm3 ved Baseline Karakteristika
CD4 Mean Change from Baseline, cells/mm3 by Baseline Characteristic
CD4% eller plasma-HIV-RNA blev ikke påvirket af vaccination.
The CD4% or plasma HIV RNA was not affected by vaccination.
CD4+ celletal gennemsnitlig
CD4+ cell count mean change from baseline (x 106/l)b
CD4+ celletal gennemsnitlig ændring fra baselineb
CD4+ cell count mean change from baselineb
CD4+ celletal ved baseline
Baseline CD4+ cell count
CD4+ procent ændring fra baselineb
CD4+ percent change from baseline
CD4+ procent ændring fra baselineb
CD4+ percent change from baselineb
CD4+-celletal ≥ 100 x 106 celler/l, er PREZISTA en gang dagligt også indiceret til behandlingserfarne børn i alderen 3 til 17 år, der vejer mindst 15 kg.
< 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 106/l, the same indication of PREZISTA once daily applies to treatment-experienced children 3 to 17 years weighing at least 15 kg.
CD4+-celletal  gennemsnitlig ændring fra baselineb
CD4+ cell count mean change from baselineb
CD4+-celletal  procent ændring fra baselineb
CD4+ percent change from baselineb
CD4+-celletal  procentændring fra baselineb
CD4+ percent change from baselineb
CD4+-celletal procent ændring fra baselineb
CD4+ percent change from baselineb
CD4-celler er en type hvide blodceller, der spiller en vigtig rolle, når kroppen skal bekæmpe infektioner.
CD4 cells are a type of white blood cell that are important in helping your body to fight infection.
CD4-celler/mm3, middelændring fra baseline
CD4 Mean Change from Baseline, cells/mm3
CD4-celletal
CD4 count
CD4-celletal (celler/mm3 ), median [interval]
CD4 cell count (cells/mm3 ), median [range]
CD4-celletal (celler/mm3) ved baseline
Baseline CD4 count (cells/mm3)
CD4-celletal (x 106/l) ved baseline
Baseline CD4 count (x 106/l)
CD4-celletal < 50
CD4-count <50
CD4-celletal gennemsnitlig ændring fra baseline (x 106/l)b
CD4 cell count mean change from baseline (x 106/l)b
CD4-celletal ≤ 50 celler/mm3
314 (242, 386)
CD4-celletal ≤ 50 celler/mm3
CD4-count ≤ 50 cells/mm3
CD4-celletal ≤ 50 celler/mm3
≤ 100,000 copies/ml
CD4-celletal ≤ 50 celler/mm3
≤ 200 cells/mm3
CD4-celletallet steg med henholdsvis 150 og 95 celler/mm3.
CD4 cell counts increased by 150 and 95 cells/mm3, respectively.
CD4-procent, median [interval]
CD4 percent, median [range]
CD4-tal < 350 celler/μl, n (%)
CD4 count < 350 cells/μl, n (%)
CD4-tælling (celler/mm3) ved baseline
Baseline CD4 count (cells/mm3)
CDAI < 150 ved både uge 30 og 54.
both Week 8 and Week 30)a 5.3
CDC hiv-kategori B eller C
CDC HIV category B or C
CDC hiv-kategori B eller C
CDC HIV category B or C 59
CDC-klasse C
CDC class C
CDLQI 0 eller 1 indikerer, at der ikke er nogen indvirkning på barnets livskvalitet.
CDLQI of 0 or 1 indicates no effect on child’s quality of life.
CDLQI 0 eller 1b
CDLQI of 0 or 1b
cefaclor, benzylpenicillin (penicillin G), ciprofloxacin mod infektioner.
Cefaclor, benzylpenicillin (penicillin G), ciprofloxacin for infections
Cefovecin afviger fra andre lignende cefalosporin-antibiotika, da det forbliver i hunden eller kattens krop i meget lang tid efter, at det er blevet indsprøjtet.
Cefovecin differs from other similar cephalosporin antibiotics as it stays in the dog’s or cat’s body for a very long time after it has been injected.
Cefovecin er et tredje generations cephalosporin med et bredt spektrum af aktivitet mod Gram- positive og Gram-negative bakterier.
Cefovecin is a third generation cephalosporin with a broad-spectrum of activity against Gram-positive and Gram-negative bacteria.
Cefovecin har in vitro aktivitet mod Staphylococcus pseudintermedius og Pasteurella multocida, som ses i forbindelse med hudinfektioner hos hunde og katte.
Cefovecin exhibits in-vitro activity against Staphylococcus pseudintermedius and Pasteurella multocida which are associated with canine and feline skin infections.
Cefovecin viser in vitro aktivitet mod Staphylococcus pseudintermedius og Pasteurella multocida i forbindelse med hudinfektioner hos hunde og katte.
Cefovecin exhibits in vitro activity against Staphylococcus pseudintermedius and Pasteurella multocida which are associated with canine and feline skin infections.
Ceftarolin er ikke virksomt mod stammer af Enterobacteriaceae, som producerer betalaktamaser med udvidet spektrum (ESBL) af familierne TEM, SHV eller CTX-M, serin-carbapenemaser (såsom KPC), metallo-betalaktamaser i klasse B eller klasse C (AmpC)-cefalosporinaser.
Ceftaroline is not active against strains of Enterobacteriaceae producing extended-spectrum beta- lactamases (ESBLs) from the TEM, SHV or CTX-M families, serine carbapenemases (such as KPC), class B metallo-beta-lactamases or class C (AmpC) cephalosporinases.
Ceftarolinfosamil (ceftarolinum fosamilum)
Ceftaroline fosamil
Ceftarolinfosamil og ceftarolin var klastogene i en in vitro-analyse af kromosomafvigelser, men der var ingen tegn på mutagen aktivitet ved Ames-test, muselymfomtest og ikke-planmæssig DNA- syntesetest (unscheduled DNA synthesis assay).
Ceftaroline fosamil and ceftaroline were clastogenic in an in vitro chromosomal aberration assay, however there was no evidence of mutagenic activity in an Ames, mouse lymphoma and unscheduled DNA synthesis assay.
Ceftarolins beta- laktamring hydrolyseres og danner den mikrobiologisk inaktive metabolit med åben ring, ceftarolin M-1.
Hydrolysis of the beta-lactam ring of ceftaroline occurs to form the microbiologically inactive, open-ring metabolite, ceftaroline M-1.
Ceftazidim er et antibiotikum kaldet cefalosporin, der tilhører den bredere gruppe af "betalaktamer".
Ceftazidime is an antibiotic called a cephalosporin, which belongs to the wider group ‘beta-lactams’.
Ceftazidim hæmmer bakteriel peptidoglycan-cellevægssyntese efter binding til penicillinbindende proteiner (PBP’er), hvilket medfører bakteriolyse og celledød.
Ceftazidime inhibits bacterial peptidoglycan cell wall synthesis following binding to penicillin binding proteins (PBPs), which leads to bacterial cell lysis and death.
Ceftazidim interfererer ikke med enzymbaserede analyser for glukosuri.
Ceftazidime does not interfere with enzyme-based tests for glycosuria.
Ceftazidim tilhører en gruppe antibiotika, som kaldes cefalosporiner.
Ceftazidime belongs to the group of antibiotics called “cephalosporins”.
Ceftazidim/avibactams farmakokinetik påvirkes ikke signifikant af køn eller race.
The pharmacokinetics of ceftazidime/avibactam is not significantly affected by gender or race.
Ceftiofur (som krystallinsk fri syre) 100 mg
Ceftiofur (as crystalline free acid) 100 mg,
Ceftiofur (som krystallinsk fri syre) 100 mg.
Ceftiofur (as crystalline free acid) 100 mg.
Ceftiofur (som krystallinsk fri syre) 100 mg/ml.
Ceftiofur (as crystalline free acid) 100 mg/ml.
Ceftiofur (som krystallinsk fri syre) 200 mg,
Ceftiofur (as crystalline free acid) 200 mg,
Ceftiofur (som krystallinsk fri syre) 200 mg.
Ceftiofur (as crystalline free acid) 200 mg.
Ceftiofur (som krystallinsk fri syre) 200 mg/ml.
Ceftiofur (as crystalline free acid) 200 mg/ml.
Ceftiofur er et tredje generations cephalosporin, som er effektivt mod mange grampositive og gramnegative bakterier.
Ceftiofur is a third generation cephalosporin antibiotic, which is active against many Gram-positive and Gram-negative pathogens.
Ceftiofur hæmmer bakteriens cellevægssyntese og har således baktericide egenskaber.
Ceftiofur inhibits the bacterial cell wall synthesis, thereby exerting bactericidal properties.
Ceftolozan i Zerbaxa er et antibiotikum af cefalosporin-typen, der tilhører den større gruppe betalactamer.
The ceftolozane in Zerbaxa is a type of antibiotic called a cephalosporin, which belongs to the wider group called ‘beta-lactams’.
ceftolozan, et antibiotikum som tilhører gruppen "cefalosporiner", og som kan dræbe visse bakterier, der medfører infektion. tazobactam, som blokerer virkningen af visse enzymer, der kaldes "beta-lactamasehæmmere".
ceftolozane, an antibiotic that belongs to the group of “cephalosporins” and which can kill certain bacteria that can cause infection; tazobactam, which blocks the action of certain enzymes called beta lactamases.
Ceftolozan/tazobactam indeholder 10,0 mmol (230 mg) natrium pr. hætteglas.
Ceftolozane/tazobactam contains 10.0 mmol (230 mg) of sodium per vial.
Ceftolozan/tazobactam skal anvendes med forsigtighed hos patienter med tidligere overfølsomhedsreaktioner af enhver anden type over for penicilliner eller andre beta-lactam- antibiotika.
Ceftolozane/tazobactam should be used with caution in patients with a history of any other type of hypersensitivity reaction to penicillins or other beta-lactam antibacterial agents.
Celecoxib (anvendes til at behandle nogle former for betændelse),
celecoxib (used to treat some forms of inflamamtion),
Celecoxib er en diarylsubstitueret pyrazol og kemisk ligner det andre non-arylaminsulfonamider (f.eks. thiazider, furosemid), men det adskiller sig fra arylaminsulfonamider (f.eks. sulfamethoxizol og andre sulfonamid-antibiotika).
Celecoxib is a diaryl-substituted pyrazole, chemically similar to other non-arylamine sulfonamides (e.g. thiazides, furosemide) but differing from arylamine sulfonamides (e.g. sulfamethoxizole and other sulfonamide antibiotics).
Celecoxib er en oral selektiv cyclooxygenase-2-hæmmer (COX-2).
Celecoxib is an oral, selective cyclooxygenase-2 (COX-2) inhibitor.
Celecoxib påvirker ikke i klinisk relevant grad farmakokinetikken af tolbutamid (CYP2C9-substrat), eller glibenclamid.
Celecoxib does not affect the pharmacokinetics of tolbutamide (CYP2C9 substrate), or glibenclamide to a clinically relevant extent.
Celecoxibs metabolisme medieres hovedsageligt af cytokrom P450 CYP2C9.
Celecoxib metabolism is primarily mediated via cytochrome P450 2C9.
Celgene Europe Limited 1 Longwalk Road
Celgene Europe Limited 1 Longwalk Road Stockley Park
Celgene Europe Ltd., 1 Longwalk Road, Stockley Park, Uxbridge, UB11 1DB, Storbritannien.
Celgene Europe Ltd., 1 Longwalk Road, Stockley Park, Uxbridge, UB11 1DB, United Kingdom.
CellCept 1 g/5 ml pulver til oral suspension
CellCept 1 g/5 ml powder for oral suspension
CellCept 1 g/5 ml pulver til oral suspension.
CellCept 1 g/5 ml powder for oral suspension.
CellCept 1 g/5 ml pulver til oral suspension:
CellCept 1 g/5 ml powder for oral suspension:
CellCept 250 mg kapsler
CellCept 250 mg capsules
CellCept 250 mg kapsler.
CellCept 250 mg capsules.
CellCept 250 mg kapsler: 1 pakning indeholder 100 kapsler (blisterkort med 10 kapsler).
CellCept 250 mg capsules: 1 carton contains 100 capsules (in blister packs of 10)
CellCept 500 mg filmovertrukne tabletter
CellCept 500 mg film-coated tablets
CellCept 500 mg filmovertrukne tabletter Mycophenolatmofetil
CellCept 500 mg film-coated tablets Mycophenolate mofetil
CellCept 500 mg filmovertrukne tabletter.
CellCept 500 mg film-coated tablets.
CellCept 500 mg pulver til koncentrat til infusionsvæske, opløsning Polysorbat 80 citronsyre saltsyre natriumchlorid
CellCept 500 mg powder for concentrate for solution for infusion polysorbate 80 citric acid hydrochloric acid sodium chloride
CellCept 500 mg pulver til koncentrat til infusionsvæske, opløsning, indeholder ikke et antibakterielt konserveringsmiddel; derfor bør rekonstitution og fortynding af lægemidlet foregå under aseptiske forhold.
CellCept 500 mg powder for concentrate for solution for infusion does not contain an antibacterial preservative; therefore, reconstitution and dilution of the product must be performed under aseptic conditions.
CellCept 500 mg pulver til koncentrat til infusionsvæske, opløsning, skal rekonstitueres og yderligere fortyndes med 5 % glucose intravenøs infusionsvæske før indgift til patienten. (Se pkt.
CellCept 500 mg powder for concentrate for solution for infusion must be reconstituted and further diluted with glucose intravenous infusion 5% prior to administration to the patient (see section 6.6).
CellCept 500 mg pulver til koncentrat til infusionsvæske, opløsning.
CellCept 500 mg powder for concentrate for solution for infusion.
CellCept bør gives med forsigtighed til patienter svær, aktiv sygdom i fordøjelsessystemet.
CellCept should be administered with caution in patients with active serious digestive system disease.
CellCept er blevet ledsaget af en højere incidens af bivirkninger fra fordøjelsessystemet inklusiv sjældne tilfælde af sår, blødning og perforation fra mavetarmkanalen.
CellCept has been associated with an increased incidence of digestive system adverse events, including infrequent cases of gastrointestinal tract ulceration, haemorrhage and perforation.
CellCept er kontraindiceret til fertile kvinder, som ikke anvender højeffektiv antikonception.
CellCept is contraindicated in women of childbearing potential who are not using highly effective contraception.
CellCept er kontraindiceret under graviditet, medmindre der ikke findes en hensigtsmæssig alternativ behandling, og for at udelukke en uønsket anvendelse under graviditet må behandling ikke initieres, uden at en negativ graviditetstest foreligger.
CellCept is contraindicated during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection.Treatment should not be initiated without providing a negative pregnancy test result to rule out unintended use in pregnancy.
CellCept er, i kombination med ciclosporin og kortikosteroider, indiceret til forebyggelse af akut transplantatafstødning hos patienter, der modtager allogene nyre-, hjerte-, eller levertransplantater.
CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.
CellCept filmovertrukne tabletter skal håndteres forsigtigt Tabletterne må ikke knuses
CellCept film-coated tablets should be handled with care Do not crush the tablets
CellCept findes i et 20 ml klart hætteglas (type I glas) med grå butylgummiprop og aluminiumssegl med aftageligt plastiklåg.
Cellcept is provided in a 20 mL type I clear glass vial with a grey butyl rubber stopper and aluminium seal with a plastic flip-off cap.
CellCept i.v. infusionsvæske må aldrig gives som en hurtig injektion eller som en bolusinjektion.
CellCept IV solution should never be administered by rapid or bolus intravenous injection.
CellCept indeholder aspartam.
CellCept contains aspartame.
CellCept indeholder sorbitol (en sukkerart).
CellCelpt contains sorbitol (a type of sugar).
CellCept kapsler skal håndteres forsigtigt
CellCept capsules should be handled with care
CellCept kapsler: Pregelatineret majsstivelse, croscarmellosenatrium, polyvidon (K-90), magnesiumstearat
CellCept capsules: pregelatinised maize starch, croscarmellose sodium, polyvidone (K-90), magnesium stearate
CellCept må ikke anvendes hos fertile kvinder, som ikke anvender højeffektiv prævention (se ptk.
CellCept should not be given to women of childbearing potential who are not using highly effective contraception (see section 4.6).
CellCept nedsætter kroppens forsvar.
CellCept reduces your body’s defences.
CellCept skal bruges sammen med anden medicin:
CellCept should be used together with other medicines:
CellCept skal gives intravenøst i de 4 første dage efter en levertransplantation og herefter skal oral administration påbegyndes så snart det tåles.
IV CellCept should continue for the first 4 days following hepatic transplant, with oral CellCept initiated as soon after this as it can be tolerated.
CellCept-kapsler må kun ordineres til patienter med en legemsoverflade på mindst 1,25 m2.
CellCept capsules should only be prescribed to patients with a body surface area of at least 1.25 m2.
Celle-associeret, levende, recombinant kalkun herpesvirus (rHVT/ND), der udtrykker fusionsprotein med Newcastle Disease Virus, avirulent stamme D-26: 2.500 – 8.000 PFU.
Cell-associated live recombinant turkey herpes virus (rHVT/ND) expressing the fusion protein of Newcastle diseases virus D-26 lentogenic strain: 2,500 – 8,000 PFU
celle-karcinom og spinocellulært karcinom)
basal cell carcinoma and squamous cell
celle-karcinom og spinocellulært karcinom),
basal cell carcinoma and squamous cell
Celleassocieret levende, rekombinant kalkunherpesvirus (stamme HTV/ILT-138) , der udviser glycoproteinerne gD og gI over for infektiøs laryngotracheitis-virus: 103.1 – 104.1 PFU1.
Cell-associated live recombinant turkey herpesvirus (strain HVT/ILT-138), expressing the glycoproteins gD and gI of infectious laryngotracheitis virus: 103.1 – 104.1 PFU1.
Celleassocieret levende, rekombinant kalkunherpesvirus (stamme HTV/ILT-138), der udviser glycoproteinerne gD og gI over for infektiøs laryngotracheitis-virus: 103.1 – 104.1 PFU1.
Cell-associated live recombinant turkey herpesvirus (strain HVT/ILT-138), expressing the glycoproteins gD and gI of infectious laryngotracheitis virus: 103.1 – 104.1 PFU1.
Celleforandringer i livmoderhalsen
Abnormal cells in your cervix
cellekarcinom og spinocellulært karcinom),
System Organ Class
Cellekultur infektiøs dosis 50 %
50% cell culture infectious dose
Cellekultur infektiøs dosis 50 %
Cell culture infectious dose 50
Cellekultur infektiøs dosis 50%
Cell culture infectious dose 50%.
Celleoptagelsen er ikke afhængig af receptorer, bindingsproteiner eller stofskifteprocesser og sker ikke ved pinocytose.
Cellular uptake does not require receptors, binding proteins or metabolic processes and does not occur by pinocytosis.
celler/mm3 (S.E.M. d)
cells/mm3 (S.E.M.d)
Celler/mm3 (S.E.M.)c
cell count cells/mm3 (S.E.M.c)
celler/mm3 (S.E.M.**d)
cells/mm3 (S.E.M.d)
Cellerne anvendes til at udfylde det mellemrum, hvor brusken er beskadiget, så de beskadigede områder repareres, og der opnås bedring i patientens symptomer i form af smerter og nedsat bevægelighed i knæet.
The cells are used to fill in the space where the cartilage has been damaged, thereby regenerating the damaged areas and helping to resolve the patient’s symptoms such as pain and problems moving the knee.
Cellerne er af human oprindelse og er genetisk modificerede med en replikationsdefekt γ-retroviral vektor, der koder for HSV-TK- og ΔLNGFR-generne således, at disse sekvenser integreres i værtscellernes genom.
The cells are of human origin and genetically modified with a replication- defective γ-retroviral vector coding for the HSV-TK and ΔLNGFR genes so that these sequences are integrated in the genome of the host cells.
Cellerne i kæmpecelletumorer i knoglerne aktiveres desuden via RANKL, og behandling med denosumab forhindrer dem i at vokse og nedbryde knoglen, og tumoren vil erstattes af normalt knoglevæv.
The cells in giant cell tumour of bone are also activated via RANKL, and treatment with denosumab prevents them from growing and breaking down bone, allowing normal bone to replace the tumour.
Cellesuspension: Opbevares og transporteres nedfrosset i flydende kvælstof (–196 °C).
Cell suspension: Store and transport frozen in liquid nitrogen (–196 °C).
Cellulitis
Frequency
cellulitis på
ite abscess,
Cellulitis på infusionsstedet (smerter og hudrødme)
Infusion site cellulitis (pain and redness of the skin)
Cellulitis på infusionsstedeta
Infusion-site cellulitisa
Cellulose, mikrokrystallinsk (E 460) Stivelse, pregelatineret (E 1404) Lactose, vandfri
Cellulose microcrystalline (E 460) Starch pregelatinised (E 1404) Lactose anhydrous
Cellulose, mikrokrystallinsk (E460) Crospovidon
Cellulose, microcrystalline (E460) Crospovidone
Cellulose, mikrokrystallinsk (E460) Lactosemonohydrat
Cellulose, microcrystalline (E460) Lactose monohydrate Hypromellose (E464)
Cellulose, mikrokrystallinsk (E460) Natriumstivelsesglycolat
Microcrystalline cellulose (E460) Sodium starch glycolate Povidone (E1201)
Cellulose, mikrokrystallinsk (E460) Titandioxid (E171)
Cellulose, microcrystalline (E460) Titanium dioxide (E171)
Cellulose, mikrokrystallinsk (E460i) Croscarmellosenatrium (E468) Magnesiumstearat
Cellulose, microcrystalline (E460i) Croscarmellose sodium (E468) Magnesium stearate
Cellulose, mikrokrystallinsk (E460i) Natriumstivelsesglycolat Type A Povidon
Lactose monohydrate Microcrystalline cellulose (E460i) Sodium starch glycolate Type A Povidone
Cellulose, mikrokrystallinsk Calciumhydrogenphosphat, vandfri Croscarmellosenatrium
Calcium Hydrogen Phosphate Anhydrous Croscarmellose Sodium
Cellulose, mikrokrystallinsk Copovidon
Cellulose microcrystalline Copovidone Crospovidone
Cellulose, mikrokrystallinsk Croscarmellosenatrium Hydroxypropylcellulose Lactosemonohydrat Magnesiumstearat Polysorbat 80
Cellulose microcrystalline Croscarmellose sodium Hydroxypropylcellulose Lactose monohydrate Magnesium stearate Polysorbate 80
Cellulose, mikrokrystallinsk Croscarmellosenatrium Magnesiumstearat
Cellulose, microcrystalline Croscarmellose sodium Magnesium stearate
Cellulose, mikrokrystallinsk Croscarmellosenatrium Povidon
Tablet core: Microcrystalline cellulose Croscarmellose sodium Povidone
Cellulose, mikrokrystallinsk Crospovidon
Cellulose microcrystalline Crospovidone
cellulose, mikrokrystallinsk crospovidon hypromellose magnesiumstearat lactosemonohydrat natriumlaurilsulfat
cellulose microcrystalline crospovidone hypromellose magnesium stearate lactose monohydrate sodium laurilsulfate
Cellulose, mikrokrystallinsk Crospovidon Lactosemonohydrat Hvedestivelse
Cellulose microcrystalline Crospovidone
Cellulose, mikrokrystallinsk Crospovidon Type A
Cellulose microcrystalline Crospovidone Type A Silica, colloidal anhydrous Magnesium stearate
Cellulose, mikrokrystallinsk Kolloidal vandfri silica Crospovidon (type A) Macrogol 6000 Hydrogeneret ricinusolie
Cellulose, microcrystalline Colloidal anhydrous silica Crospovidone (type A) Macrogol 6000 Hydrogenated castor oil
Cellulose, mikrokrystallinsk Lactosemonohydrat Hypromelloseacetatsuccinat Croscarmellosenatrium Natriumlaurilsulfat
Cellulose, microcrystalline Lactose monohydrate Hypromellose acetate succinate Croscarmellose sodium Sodium laurilsulfate
Cellulose, mikrokrystallinsk Magnesiumstearat
Cellulose, microcrystalline Magnesium stearate Silica, colloidal anhydrous
Cellulose, mikrokrystallinsk Mannitol
Cellulose, microcrystalline Mannitol
Cellulose, mikrokrystallinsk Natriumlaurilsulfat Hydrogeneret vegetabilsk olie
Cellulose, microcrystalline Sodium laurilsulfate Hydrogenated vegetable oil
Cellulose, mikrokrystallinsk Natriumstivelseglycoat (type A) Magnesiumstearat
Sodium starch glycolate (type A) Magnesium stearate
Cellulose, mikrokrystallinsk Natriumstivelsesglycolat Magnesiumstearat
Tablet core Microcrystalline cellulose Sodium starch glycolate Magnesium stearate
Cellulose, mikrokrystallinsk Povidon (K-30) Crospovidon
Cellulose, microcrystalline Povidone (K-30) Crospovidone
Cellulose, mikrokrystallinsk Silica, hydrofob kolloid Croscarmellosenatrium Magnesiumstearat
Microcrystalline cellulose Silica, hydrophobic colloidal Croscarmellose sodium Magnesium stearate
Cellulose, mikrokrystallinsk Silika, kolloid vandfri
Silica, colloidal anhydrous
cellulose, mikrokrystallinsk stivelse, pregelatineret
microcrystalline cellulose pregelatinized starch sodium starch glycolate magnesium stearate
cellulose, mikrokrystallinsk stivelse, pregelatineret natriumstivelsesglycolat magnesiumstearat
microcrystalline cellulose pregelatinized starch sodium starch glycolate magnesium stearate
Cellulose, mikrokrystallinsk Tørret kødaroma
Iron oxide yellow Cellulose, microcrystalline Meat Dry Flavour